IMPACT OF THE COVID-19 PANDEMIC ON HEPATITIS C VIRUS SCREENING IN DRUG TREATMENT SETTINGS IN ENGLAND: AN 18-MONTH ANALYSIS BETWEEN SEPT19-FEB21

Salehi S1, Kemp T2, Hampton H3, Smith S4, Fair R5, John R6, Smethurst P7

1Medical Affairs, Gilead Sciences Ltd., London, United Kingdom 2Change Grow Live, Leeds, United Kingdom 3We Are With You, London, United Kingdom 4Human Kind, Manchester, United Kingdom 5Inclusion (part of) Midlands Partnership NHS Foundation Trust, 6Turning Point, London, United Kingdom 7Patient Access to Care, Gilead Sciences Ltd., London, United Kingdom

Background: Individuals who currently or have ever injected drugs are at risk of hepatitis C virus (HCV) infection. Protocols developed by drug treatment services (DTS) allow at-risk individuals to be tested and linked to appropriate care. This analysis assessed the impact of the COVID-19 pandemic on HCV testing in DTS in England.


Results: Between Sept2019-Feb21; 32,250 individuals were tested for HCV. Where data were available, 69% were male (n=22,342), 19% current injectors (n=4,922) and 31% previous injectors (n=7,982). There were significantly fewer tests conducted during the periods of National lockdown and Recovery, versus Baseline (p=0.03 and 0.018, respectively). Postal testing was introduced by some services in Sept2020. Where data are available, they accounted for 15% (n=644) of tests conducted Sept20-Nov20 and 20% (n=863) Dec20-Feb21.

During the Recovery period there were a higher number of clients testing positive for HCV antibody and PCR versus Baseline; 30% vs 20% (p=0.002) and 13% vs 8.5% (p=0.0062), respectively. This may, in part, be explained by a higher proportion of Current Injectors tested between Sept20-Feb21 versus Baseline; 22.5% versus 18.5% (p=0.01). There were, however, no statistically significant differences in age, gender or injecting status.

Conclusion: Restrictions introduced in England to control the COVID-19 pandemic significantly impacted the number of HCV tests performed. Adaptation of pathways, including postal and outreach testing, have increased the proportion of service users accessing tests, particularly Current Injectors. Continued adaptations will further limit the impact of further restrictions, such as those imposed between Jan-Apr21.

Figure:
Disclosure of Interest Statement:
Data were provided as part of a Gilead partnership with the named drug treatment service providers, which includes funding for data analysts and HCV coordinators. SS and PS are employees of Gilead Sciences, UK.